3.
恩沙替尼和同类药治疗ALK阳性NSCLC的疗效
Efficacy of Ensatinib and similar drugs in the treatment of ALK-positive NSCLC
| Drug | ORR | DCR | mPFS (mon) | DOR (mon) | iORR | iDCR | |
| DCR: disease control rate; mPFS: median progression-free survival; DOR: duration of response; iDCR: intracranial disease control rate; NA: not available; NR: not reached. | |||||||
| Second-line therapy | |||||||
| Ensartinib | NCT01625234 | 69.0% | 96.6% | 9.0 | 7.4 | 62.5% | 100.0% |
| NCT03215693 | 52.0% | 93.0% | 9.6 | NA | 70.0% | 98.0% | |
| Ceritinib | ASCEND-1 | 56.0% | 74.2% | 6.9 | 8.3 | 36.0% | 61.0% |
| ASCEND-2 | 38.6% | 77.1% | 5.7 | 9.7 | 45.0% | 80.0% | |
| Alectinib | NP28761 | 48.0% | 80.0% | 8.1 | 13.5 | 75.0% | 89.0% |
| NP28673 | 50.0% | 79.0% | 8.9 | 11.2 | 57.0% | 83.0% | |
| AF-002JG | 55.0% | 90.0% | NA | NA | 52.0% | 90.0% | |
| Brigatinib | NCT01449461 | 62.0% | NA | 13.4 | NA | 50.0% | NA |
| ALTA (90 mg) | 45.0% | 82.0% | 9.2 | 13.8 | 42.0% | 85.0% | |
| ALTA (90 mg→180 mg) | 54.0% | 86.0% | 12.9 | 11.1 | 67.0% | 83.0% | |
| Lorlatinib | NCT01970865 | 39.0%-73.0% | NA | NA | 7-NR | 46.0%-68.0% | NA |
| First-line therapy | |||||||
| Ensartinib | NCT01625234 | 80.0% | 86.7% | 26.2 | 24.4 | 100.0% | 100.0% |
| Crizotinib | PROFILE 1014/1029 | 74.0%-87.5% | 91.2% | 10.9-11.1 | 11.3 | NA | NA |
| PROFILE 1005/1007 | NA | NA | NA | NA | 18.0%-33.0% | 56.0%-62.0% | |
| Ceritinib | ASCEND-1 | 72.0% | 89.0% | 18.4 | 17.0 | 63.0% | 63.0% |
| Alectinib | ALEX | 82.9% | 88.8% | 25.7 | NR | 85.7% | NA |
| Brigatinib | ALTA-1L | 71.0% | NA | NR | NR | 78.0% | NA |